Market reaction
Iovance Biotherapeutics Inc (NASDAQ:IOVA) shares rose 3.2% in after-hours trading Wednesday after the Therapeutic Goods Administration of Australia approved Amtagvi (lifileucel) with conditions for use in previously treated advanced melanoma. The move came as the company outlined plans to expand its treatment network in Australia to support the new authorization.
Scope of the approval
The TGA granted conditional marketing authorization for Amtagvi, a tumor-derived autologous T cell immunotherapy. The approval covers adult patients with unresectable or metastatic melanoma who have previously received a PD-1 blocking antibody. For patients with a BRAF V600 mutation, the indicated population also includes those previously treated with a BRAF inhibitor with or without a MEK inhibitor.
Clinical and regulatory context
This authorization is the third global marketing approval for Amtagvi and is notable as the first time a T cell therapy has been approved in Australia for a solid tumor cancer. The TGA decision also establishes the first available treatment option in Australia for advanced melanoma after prior anti-PD-1 therapy and targeted therapy.
The approval was supported by safety and efficacy findings from the global, multicenter C-144-01 trial, a Phase 2 study that evaluated Amtagvi in patients with advanced melanoma previously treated with anti-PD-1 therapy and targeted therapy where applicable. The Phase 2 trial enrolled patients with metastatic melanoma who had received at least one prior systemic therapy, including a PD-1 blocking antibody, and, for those with BRAF V600 mutation, prior BRAF inhibitor therapy or combined BRAF and MEK inhibitor therapy.
Efficacy determination in the trial was based on objective response rate and duration of response as assessed by an Independent Review Committee using Response Evaluation Criteria In Solid Tumors version 1.1.
Company actions and epidemiology
As part of its rollout plan, Iovance said it is authorizing its first Australian treatment center to deliver Amtagvi in a market noted for a particularly high burden of disease. Australia has the highest rate of melanoma worldwide, with an estimated 17,000 new cases diagnosed annually and more than 1,500 deaths each year, figures the company cited in explaining the market rationale.
Implications for investors and the market
The approval and related operational steps contributed to the after-hours stock uptick. The clinical evidence supporting the authorization derives from a Phase 2 study and an independent review of response measures, which formed the basis for the TGA's conditional grant.
Summary of key items
- Australia's TGA granted conditional approval for Amtagvi (lifileucel) in previously treated advanced melanoma.
- The authorization is based on data from the global C-144-01 Phase 2 trial, with efficacy assessed by objective response rate and duration of response per RECIST v1.1.
- Iovance is authorizing its first Australian treatment center; the country has an estimated 17,000 new melanoma cases and over 1,500 deaths annually.